Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents
Background: Adherence to oral hypoglycemic agents (OHAs) is important for adequate glycemic control and prevention of future complications in patients with type 2 diabetes. Objective: To examine the impact of depression on adherence to OHAs in patients newly diagnosed with type 2 diabetes. Methods:...
Gespeichert in:
| Veröffentlicht in: | The Annals of pharmacotherapy 2006-04, Vol.40 (4), p.605-611 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 611 |
|---|---|
| container_issue | 4 |
| container_start_page | 605 |
| container_title | The Annals of pharmacotherapy |
| container_volume | 40 |
| creator | Kalsekar, Iftekhar D Madhavan, Suresh S Amonkar, Mayur M Makela, Eugene H Scott, Virginia G Douglas, Stratford M Elswick, Betsy L Meredith |
| description | Background:
Adherence to oral hypoglycemic agents (OHAs) is important for adequate glycemic control and prevention of future complications in patients with type 2 diabetes.
Objective:
To examine the impact of depression on adherence to OHAs in patients newly diagnosed with type 2 diabetes.
Methods:
Patients newly diagnosed with type 2 diabetes during a 4 year period were identified from a Medicaid claims database. Presence of preexisting depression was determined on the basis of ICD-9-CM codes. Adherence to OHAs was computed using prescription refill data for a 12 month follow-up period from the date of the index OHA prescription. Two separate adherence indices (Medication Possession Ratio-1 [MPR-1], Medication Possession Ratio-2 [MPR-2]) were computed. The impact of depression on adherence was assessed after controlling for confounders such as demographics, comorbidity, provider interaction, complexity of regimen, and diabetes severity.
Results:
A total of 1326 newly diagnosed patients with type 2 diabetes were identified (depressed = 471; nondepressed = 855). Results of the study indicated that patients with depression had significantly lower adherence (MPR-1 86%; MPR-2 66%) to OHAs compared with patients without depression (MPR-1 89%; MPR-2 73%). Multivariate results indicated that depression was a significant predictor of adherence, with depressed patients being 3–6% less adherent to OHAs than nondepressed patients, after controlling for confounding factors.
Conclusions:
Depression significantly impacts adherence to OHAs in patients with type 2 diabetes. The study results imply that depression screening and treatment need to be included in the protocol for management of patients with type 2 diabetes. |
| doi_str_mv | 10.1345/aph.1G606 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67833060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1G606</sage_id><sourcerecordid>67833060</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-5635748bd4fc1e66bc56293aa7af8308234f1b3d5c455d0b4cf6135473ca842d3</originalsourceid><addsrcrecordid>eNptkEtr3DAQgEVpaR7toX-g6NJADk71lre3JWmTQCA9pLeCGMvjtYJflbyY_fdVGsNeepo5fHwzfIR84uyKS6W_wtRe8VvDzBtyyrUShRGWvc07M6xgomQn5CylZ8bYhovNe3LCjdbcmvKU_L7BKWJKYRxoGOhPmAMOc6JLmFv6dJiQCnoToMIZ0zd630_gZ5rZbd1ixMEjnUf6GKGjd4dp3HUHj33wdLt7sXwg7xroEn5c5zn59eP70_Vd8fB4e3-9fSi8tGoutJHaqrKqVeM5GlN5bcRGAlhoSslKIVXDK1lrr7SuWaV8Y7jUykoPpRK1PCcXr94pjn_2mGbXh-Sx62DAcZ-csaWUuUUGL19BH8eUIjZuiqGHeHCcuZeULqd0_1Jm9vMq3Vc91kdybZeBLysAyUPXRBh8SEfOWlZKLo7fJdihex73ccgx_ntxFbZh1y4hoks9dF2-z92yLIo55QzT8i_t-ZQX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67833060</pqid></control><display><type>article</type><title>Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Kalsekar, Iftekhar D ; Madhavan, Suresh S ; Amonkar, Mayur M ; Makela, Eugene H ; Scott, Virginia G ; Douglas, Stratford M ; Elswick, Betsy L Meredith</creator><creatorcontrib>Kalsekar, Iftekhar D ; Madhavan, Suresh S ; Amonkar, Mayur M ; Makela, Eugene H ; Scott, Virginia G ; Douglas, Stratford M ; Elswick, Betsy L Meredith</creatorcontrib><description>Background:
Adherence to oral hypoglycemic agents (OHAs) is important for adequate glycemic control and prevention of future complications in patients with type 2 diabetes.
Objective:
To examine the impact of depression on adherence to OHAs in patients newly diagnosed with type 2 diabetes.
Methods:
Patients newly diagnosed with type 2 diabetes during a 4 year period were identified from a Medicaid claims database. Presence of preexisting depression was determined on the basis of ICD-9-CM codes. Adherence to OHAs was computed using prescription refill data for a 12 month follow-up period from the date of the index OHA prescription. Two separate adherence indices (Medication Possession Ratio-1 [MPR-1], Medication Possession Ratio-2 [MPR-2]) were computed. The impact of depression on adherence was assessed after controlling for confounders such as demographics, comorbidity, provider interaction, complexity of regimen, and diabetes severity.
Results:
A total of 1326 newly diagnosed patients with type 2 diabetes were identified (depressed = 471; nondepressed = 855). Results of the study indicated that patients with depression had significantly lower adherence (MPR-1 86%; MPR-2 66%) to OHAs compared with patients without depression (MPR-1 89%; MPR-2 73%). Multivariate results indicated that depression was a significant predictor of adherence, with depressed patients being 3–6% less adherent to OHAs than nondepressed patients, after controlling for confounding factors.
Conclusions:
Depression significantly impacts adherence to OHAs in patients with type 2 diabetes. The study results imply that depression screening and treatment need to be included in the protocol for management of patients with type 2 diabetes.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1G606</identifier><identifier>PMID: 16551768</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Administration, Oral ; Biological and medical sciences ; Cohort Studies ; Depression - prevention & control ; Depression - psychology ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - psychology ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Patient Compliance - psychology ; Pharmacology. Drug treatments ; Regression Analysis ; Retrospective Studies</subject><ispartof>The Annals of pharmacotherapy, 2006-04, Vol.40 (4), p.605-611</ispartof><rights>Copyright © 2006 Harvey Whitney Books Company</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-5635748bd4fc1e66bc56293aa7af8308234f1b3d5c455d0b4cf6135473ca842d3</citedby><cites>FETCH-LOGICAL-c374t-5635748bd4fc1e66bc56293aa7af8308234f1b3d5c455d0b4cf6135473ca842d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1G606$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1G606$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17708312$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16551768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kalsekar, Iftekhar D</creatorcontrib><creatorcontrib>Madhavan, Suresh S</creatorcontrib><creatorcontrib>Amonkar, Mayur M</creatorcontrib><creatorcontrib>Makela, Eugene H</creatorcontrib><creatorcontrib>Scott, Virginia G</creatorcontrib><creatorcontrib>Douglas, Stratford M</creatorcontrib><creatorcontrib>Elswick, Betsy L Meredith</creatorcontrib><title>Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>Background:
Adherence to oral hypoglycemic agents (OHAs) is important for adequate glycemic control and prevention of future complications in patients with type 2 diabetes.
Objective:
To examine the impact of depression on adherence to OHAs in patients newly diagnosed with type 2 diabetes.
Methods:
Patients newly diagnosed with type 2 diabetes during a 4 year period were identified from a Medicaid claims database. Presence of preexisting depression was determined on the basis of ICD-9-CM codes. Adherence to OHAs was computed using prescription refill data for a 12 month follow-up period from the date of the index OHA prescription. Two separate adherence indices (Medication Possession Ratio-1 [MPR-1], Medication Possession Ratio-2 [MPR-2]) were computed. The impact of depression on adherence was assessed after controlling for confounders such as demographics, comorbidity, provider interaction, complexity of regimen, and diabetes severity.
Results:
A total of 1326 newly diagnosed patients with type 2 diabetes were identified (depressed = 471; nondepressed = 855). Results of the study indicated that patients with depression had significantly lower adherence (MPR-1 86%; MPR-2 66%) to OHAs compared with patients without depression (MPR-1 89%; MPR-2 73%). Multivariate results indicated that depression was a significant predictor of adherence, with depressed patients being 3–6% less adherent to OHAs than nondepressed patients, after controlling for confounding factors.
Conclusions:
Depression significantly impacts adherence to OHAs in patients with type 2 diabetes. The study results imply that depression screening and treatment need to be included in the protocol for management of patients with type 2 diabetes.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Depression - prevention & control</subject><subject>Depression - psychology</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - psychology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patient Compliance - psychology</subject><subject>Pharmacology. Drug treatments</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtr3DAQgEVpaR7toX-g6NJADk71lre3JWmTQCA9pLeCGMvjtYJflbyY_fdVGsNeepo5fHwzfIR84uyKS6W_wtRe8VvDzBtyyrUShRGWvc07M6xgomQn5CylZ8bYhovNe3LCjdbcmvKU_L7BKWJKYRxoGOhPmAMOc6JLmFv6dJiQCnoToMIZ0zd630_gZ5rZbd1ixMEjnUf6GKGjd4dp3HUHj33wdLt7sXwg7xroEn5c5zn59eP70_Vd8fB4e3-9fSi8tGoutJHaqrKqVeM5GlN5bcRGAlhoSslKIVXDK1lrr7SuWaV8Y7jUykoPpRK1PCcXr94pjn_2mGbXh-Sx62DAcZ-csaWUuUUGL19BH8eUIjZuiqGHeHCcuZeULqd0_1Jm9vMq3Vc91kdybZeBLysAyUPXRBh8SEfOWlZKLo7fJdihex73ccgx_ntxFbZh1y4hoks9dF2-z92yLIo55QzT8i_t-ZQX</recordid><startdate>20060401</startdate><enddate>20060401</enddate><creator>Kalsekar, Iftekhar D</creator><creator>Madhavan, Suresh S</creator><creator>Amonkar, Mayur M</creator><creator>Makela, Eugene H</creator><creator>Scott, Virginia G</creator><creator>Douglas, Stratford M</creator><creator>Elswick, Betsy L Meredith</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060401</creationdate><title>Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents</title><author>Kalsekar, Iftekhar D ; Madhavan, Suresh S ; Amonkar, Mayur M ; Makela, Eugene H ; Scott, Virginia G ; Douglas, Stratford M ; Elswick, Betsy L Meredith</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-5635748bd4fc1e66bc56293aa7af8308234f1b3d5c455d0b4cf6135473ca842d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Depression - prevention & control</topic><topic>Depression - psychology</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - psychology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patient Compliance - psychology</topic><topic>Pharmacology. Drug treatments</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalsekar, Iftekhar D</creatorcontrib><creatorcontrib>Madhavan, Suresh S</creatorcontrib><creatorcontrib>Amonkar, Mayur M</creatorcontrib><creatorcontrib>Makela, Eugene H</creatorcontrib><creatorcontrib>Scott, Virginia G</creatorcontrib><creatorcontrib>Douglas, Stratford M</creatorcontrib><creatorcontrib>Elswick, Betsy L Meredith</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalsekar, Iftekhar D</au><au>Madhavan, Suresh S</au><au>Amonkar, Mayur M</au><au>Makela, Eugene H</au><au>Scott, Virginia G</au><au>Douglas, Stratford M</au><au>Elswick, Betsy L Meredith</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2006-04-01</date><risdate>2006</risdate><volume>40</volume><issue>4</issue><spage>605</spage><epage>611</epage><pages>605-611</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>Background:
Adherence to oral hypoglycemic agents (OHAs) is important for adequate glycemic control and prevention of future complications in patients with type 2 diabetes.
Objective:
To examine the impact of depression on adherence to OHAs in patients newly diagnosed with type 2 diabetes.
Methods:
Patients newly diagnosed with type 2 diabetes during a 4 year period were identified from a Medicaid claims database. Presence of preexisting depression was determined on the basis of ICD-9-CM codes. Adherence to OHAs was computed using prescription refill data for a 12 month follow-up period from the date of the index OHA prescription. Two separate adherence indices (Medication Possession Ratio-1 [MPR-1], Medication Possession Ratio-2 [MPR-2]) were computed. The impact of depression on adherence was assessed after controlling for confounders such as demographics, comorbidity, provider interaction, complexity of regimen, and diabetes severity.
Results:
A total of 1326 newly diagnosed patients with type 2 diabetes were identified (depressed = 471; nondepressed = 855). Results of the study indicated that patients with depression had significantly lower adherence (MPR-1 86%; MPR-2 66%) to OHAs compared with patients without depression (MPR-1 89%; MPR-2 73%). Multivariate results indicated that depression was a significant predictor of adherence, with depressed patients being 3–6% less adherent to OHAs than nondepressed patients, after controlling for confounding factors.
Conclusions:
Depression significantly impacts adherence to OHAs in patients with type 2 diabetes. The study results imply that depression screening and treatment need to be included in the protocol for management of patients with type 2 diabetes.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>16551768</pmid><doi>10.1345/aph.1G606</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | The Annals of pharmacotherapy, 2006-04, Vol.40 (4), p.605-611 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67833060 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Administration, Oral Biological and medical sciences Cohort Studies Depression - prevention & control Depression - psychology Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - psychology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Male Medical sciences Middle Aged Patient Compliance - psychology Pharmacology. Drug treatments Regression Analysis Retrospective Studies |
| title | Depression in Patients with Type 2 Diabetes: Impact on Adherence to Oral Hypoglycemic Agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A24%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Depression%20in%20Patients%20with%20Type%202%20Diabetes:%20Impact%20on%20Adherence%20to%20Oral%20Hypoglycemic%20Agents&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Kalsekar,%20Iftekhar%20D&rft.date=2006-04-01&rft.volume=40&rft.issue=4&rft.spage=605&rft.epage=611&rft.pages=605-611&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1G606&rft_dat=%3Cproquest_cross%3E67833060%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67833060&rft_id=info:pmid/16551768&rft_sage_id=10.1345_aph.1G606&rfr_iscdi=true |